KATELYN LLEWELLYN: Open Payments
NPI 1437489978 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$728 in 28 payments from 10 companies in 2025. Trend: 2023 $18 · 2024 $116 · 2025 $728
Food & beverage: $728
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $225 |
| Teva Pharmaceuticals USA, Inc. | 5 | $170 |
| Alkermes, Inc. | 4 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $75 |
| ABBVIE INC. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| HARMONY BIOSCIENCES LLC | 1 | $22 |
| Braeburn Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
Products named: SPRAVATO, UZEDY, ARISTADA, INVEGA SUSTENNA, CAPLYTA, VRAYLAR, AUSTEDO XR, INGREZZA.
Industry payments across PA — which companies pay providers there.
